173 related articles for article (PubMed ID: 7117792)
1. First-order clearance of plasma galactose: the effect of liver disease.
Henderson JM; Kutner MH; Bain RP
Gastroenterology; 1982 Nov; 83(5):1090-6. PubMed ID: 7117792
[TBL] [Abstract][Full Text] [Related]
2. Effective liver blood flow: determination by galactose clearance.
Henderson JM; Hanna SS
Can J Surg; 1983 Mar; 26(2):129-32. PubMed ID: 6824999
[TBL] [Abstract][Full Text] [Related]
3. Galactose loading tests in patients with hepatocellular carcinoma for the assessment of chemotherapy.
Buzzelli G; Meacci E; Smorlesi C; Chiarantini E; Birardi A; Gentilini P
Chemioterapia; 1987 Aug; 6(4):306-9. PubMed ID: 2820595
[TBL] [Abstract][Full Text] [Related]
4. Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: dependence on liver cell failure.
Fabbri A; Marchesini G; Bianchi G; Bugianesi E; Bortoluzzi L; Zoli M; Pisi E
Hepatology; 1993 Jul; 18(1):28-35. PubMed ID: 8325618
[TBL] [Abstract][Full Text] [Related]
5. Sorbitol clearance: a parameter reflecting liver plasma flow in the rat.
Molino G; Avagnina P; Cavanna A; Ballarè M; Torchio M; Bona B; Belforte G
Res Commun Chem Pathol Pharmacol; 1986 Apr; 52(1):119-32. PubMed ID: 3715193
[TBL] [Abstract][Full Text] [Related]
6. Hepatic galactose elimination kinetics in the intact pig.
Keiding S; Johansen S; Winkler K
Scand J Clin Lab Invest; 1982 May; 42(3):253-9. PubMed ID: 7134810
[TBL] [Abstract][Full Text] [Related]
7. Measurement of liver blood flow by galactose clearance.
Hanna SS
Can J Surg; 1984 May; 27(3):218-20. PubMed ID: 6722669
[TBL] [Abstract][Full Text] [Related]
8. The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient.
Chauvin M; Bonnet F; Montembault C; Levron JC; Viars P
Anesth Analg; 1986 Oct; 65(10):999-1003. PubMed ID: 2875679
[TBL] [Abstract][Full Text] [Related]
9. Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis.
Merkel C; Gatta A; Caregaro L; Sacerdoti D; Rondana M; Ruol A
Scand J Clin Lab Invest; 1987 Nov; 47(7):667-72. PubMed ID: 2891182
[TBL] [Abstract][Full Text] [Related]
10. Metabolic handling of orally administered glucose in cirrhosis.
Kruszynska YT; Meyer-Alber A; Darakhshan F; Home PD; McIntyre N
J Clin Invest; 1993 Mar; 91(3):1057-66. PubMed ID: 8450036
[TBL] [Abstract][Full Text] [Related]
11. Hepatic clearance of D-sorbitol. Noninvasive test for evaluating functional liver plasma flow.
Molino G; Cavanna A; Avagnina P; Ballaré M; Torchio M
Dig Dis Sci; 1987 Jul; 32(7):753-8. PubMed ID: 3595388
[TBL] [Abstract][Full Text] [Related]
12. The lumped constant for the galactose analog 2-18F-fluoro-2-deoxy-D-galactose is increased in patients with parenchymal liver disease.
Mikkelsen KS; Sørensen M; Frisch K; Villadsen GE; Bibby BM; Keiding S
J Nucl Med; 2014 Apr; 55(4):590-4. PubMed ID: 24591487
[TBL] [Abstract][Full Text] [Related]
13. Glucose kinetics and splanchnic uptake following mixed meal ingestion in cirrhotic-diabetic subjects.
Kiwanuka E; Barazzoni R; Tessari P
Diabetes Nutr Metab; 2001 Dec; 14(6):315-24. PubMed ID: 11853363
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone.
Egfjord M
Acta Physiol Scand Suppl; 1995; 627():1-42. PubMed ID: 8848946
[TBL] [Abstract][Full Text] [Related]
15. Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhosis.
Callaghan R; Desmond PV; Paull P; Mashford ML
Hepatology; 1993 Jul; 18(1):54-60. PubMed ID: 8325621
[TBL] [Abstract][Full Text] [Related]
16. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction.
Marshall JP; Salt WB; Elam RO; Wilkinson GR; Schenker S
Gastroenterology; 1977 Dec; 73(6):1388-92. PubMed ID: 913979
[TBL] [Abstract][Full Text] [Related]
17. Splanchnic galactose uptake in patients with cirrhosis during continuous infusion.
Lindskov J; Ranek L; Tygstrup N; Winkler K
Clin Physiol; 1983 Apr; 3(2):179-85. PubMed ID: 6682739
[TBL] [Abstract][Full Text] [Related]
18. [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)].
Richter E; Gallenkamp H; Keller B; Brachtel D; Zilly W; Breimer DD
Z Gastroenterol; 1977 Jun; 15(6):381-8. PubMed ID: 888488
[TBL] [Abstract][Full Text] [Related]
19. Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist.
Imawaka H; Sugiyama Y
J Pharmacol Exp Ther; 1998 Mar; 284(3):949-57. PubMed ID: 9495854
[TBL] [Abstract][Full Text] [Related]
20. The effect of liver disease on urine caffeine metabolite ratios.
Denaro CP; Wilson M; Jacob P; Benowitz NL
Clin Pharmacol Ther; 1996 Jun; 59(6):624-35. PubMed ID: 8681487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
